Header
For Healthcare Professionals

For patients with CV disease and type 2 diabetes*

JARDIANCE® helps you DO MORE than reduce HbA1c1,2

group-3@3x
group-3@3x


RRR in CV death: HR=0.62; 95% CI: 0.49, 0.77; p<0.001.1,2

RRR in hospitalisation for heart failure: HR=0.65; 95% CI: 0.50, 0.85; p=0.002.1,2

RRR in incident or worsening nephropathy: HR=0.61; 95% CI: 0.53, 0.70; p<0.001.3

  1. JARDIANCE® prescribing information, version 20-Jan-2023. Boehringer Ingelheim India Pvt Ltd.

  2. Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.

  3. Häring HU, Merker L, Seewaldt-Becker E, et al; EMPA-REG MET  Trial Investigators. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37(6):1650-1659.

  • *Adult patients with insufficiency controlled type 2 diabetes and CAD, PAD, or a history of MI or stroke.1,2
  • ‡The 38% RRR in CV death was achieved in the overall EMPA-REG OUTCOME® population for the duration of the trial (HR=0.62; 95% CI: 0.49, 0.77; p<0.001).2
  • ‡Pooled data from 10-and 25-mg doses of JARDIANCE®; both doses showed a comparable reduction in the risk of CV death.1,2
  • ‡Hospitalization for heart failure was a secondary CV outcome in the EMPA-REG OUTCOME® trial (HR=0.65; 95% Cl: 0.50, 0.85; p=0.002).2
  • ‡Pooled data from 10 mg and 25 mg doses of JARDIANCE®; both doses showed a comparable reduction in the risk of hospitalization for heart failure and incident or worsening nephropathy.1,3
  • **Incident or worsening nephropathy is defined as progression to macroalbuminuria, doubling of serum creatinine, eGFR of ≤45 mL/min/1.73 m2; initiation of renal replacement therapy; death from renal disease. Incident or worsening nephropathy was a prespecified component of the secondary microvascular CV outcome in the EMPA-REG OUTCOME® trial (HR=0.61; 95% CI: 0.53, 0.70; p<0.001) for JARDIANCE® (12.7%) versus placebo (18.8%).3
  • ‡Standard of care included CV medications and glucose-lowering agents given at the discretion of physicians.1,2
  • ACEi=angiotensin-converting enzyme inhibitor; ARB=angiotensin receptor blocker; CAD=coronary artery disease; CI=confidence interval; CV=cardiovascular; eGFR=estimated glomerular filtration rate; HR=hazard ratio; MI=myocardial infarction; PAD=peripheral artery disease; RRR=relative risk reduction.

For patients with CV disease and type 2 diabetes*

CV benefits observed with JARDIANCE® are primarily driven by mechanisms beyond conventional CV risk factor¤ reductions1

Proportion of observed risk reductions attributable to changes in conventional risk factors‡§1

group-4
group-4

  1. Coleman RL, Gray AM, Broedl UC, et al. Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk levels? Diabetes Obes Metab. 2020;22(7):1151-1156.

  2. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, 
    cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
    (EMPA-REG OUTCOME® results and the publication’s Supplementary Appendix.)

  • *Adult patients with insufficiently controlled type 2 diabetes and CAD, PAD, or a history of MI or stroke.2
  •  †Conventional risk factors included HbA1c, cholesterol, systolic BP, and presence of comorbidities.
  • ‡Post hoc analyses of 3-year EMPA-REG OUTCOME® CV event rates using a T2D-specific clinical outcomes simulation model applied to annual patient-level data.
  • §Percentage values shown are observed risk reductions for JARDIANCE® for each outcome (grey bars) and the proportion of these that is explained by the changes to conventional risk factors (green bars).
  • BP, blood pressure; CAD, coronary artery disease; CI, confidence interval; CV, cardiovascular; HbA1c, glycated haemoglobin; HR, hazard ratio; MI, myocardial infarction; P, prevalence; PAD, peripheral artery disease; T2D, type 2 diabetes.

For patients with CV disease and type 2 diabetes*

JARDIANCE® demonstrated reduction in the risk of CV death- early and sustained1,2

JARDIANCE® demonstrated reduction in the risk of CV death- early and sustained1,2
JARDIANCE® demonstrated reduction in the risk of CV death- early and sustained1,2

For patients with type 2 diabetes and CV disease*

JARDIANCE® reduced the risk of CV death or HHF in as early as 
1 month5

JARDIANCE® reduced the risk of CV death or HHF in as early as 1 month5
JARDIANCE® reduced the risk of CV death or HHF in as early as 1 month5

For your patients with type 2 diabetes and CV disease*

JARDIANCE® reduced the risk of CV death in as early as 
2 months5

In EMPA-REG OUTCOME®, JARDIANCE® reduced the relative risk of CV death by 38%1,2

JARDIANCE® reduced the risk of CV death in as early as 2 months5
JARDIANCE® reduced the risk of CV death in as early as 2 months5

  1. JARDIANCE® prescribing information, version 20-Jan-2023. Boehringer Ingelheim India Pvt Ltd.

  2. Zinman B, Wanner C, Lachin J, et al; EMPA-REG OUTCOME® Investigators. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. (EMPA-REG OUTCOME® results and the publication’s Supplementary Appendix for certain baseline characteristics).

  3. Fitchett D, Inzucchi SE, Lachin JM, et al; EMPA-REG OUTCOME® Investigators. Cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular disease. J Am Coll Cardiol. 2018;71(3):364-367.

  4. Inzucchi SE, Kosiborod M, Fitchett D, et al. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control. Circulation. 2018;138:1904-1907.

  5. Claggett B, Lachin JM, Hantel S, et al. Long-term benefit of empagliflozin on life expectancy in patients with type 2 diabetes mellitus and established cardiovascular disease: Survival estimates from the EMPA-REG OUTCOME trial. Circulation. 2018;138:1599-1601.

  • *Adult patients with insufficiently controlled type 2 diabetes and CAD, PAD, or a history of MI or stroke.1,2
  • †The 38% RRR in CV death was achieved in the overall EMPA-REG OUTCOME® population for the duration of the trial (HR=0.62; 95% CI: 0.49, 0.77; p<0.001).1,2
  • ‡Pooled data from 10 mg and 25 mg doses of JARDIANCE®; both doses showed a comparable reduction in the risk of CV death.1,2
  • §A post-hoc analysis of data from the EMPA-REG OUTCOME® trial by baseline HbA1c subgroups. EMPA-REG OUTCOME® was not powered to show differences between subgroups.2,5
  • ||Hazard ratios are related to CV death: HbA1c <7% HR=0.30 (95% CI: 0.12, 0.80); HbA1c 7% to <8% HR=0.59 (95% CI: 0.42, 0.83); HbA1c 8% to <9% HR=0.67 (95% CI: 0.45, 0.99); HbA1c ≥9% HR=0.76 (95% CI: 0.44, 1.31); p=0.41 for interaction.5
  • Standard of care included CV medications and glucose-lowering agents given at the discretion of physicians.
  • ACEi=angiotensin-converting enzyme inhibitor; ARB=angiotensin receptor blocker; CAD=coronary artery disease; CI=confidence interval; CV=cardiovascular; HbA1c=hemoglobin A1c; HR=hazard ratio; MI=myocardial infarction; PAD=peripheral artery disease; RRR=relative risk reduction.
01-elements-placeholder-card
EMPRISE

EMPAGLIFLOZIN REAL-WORLD EFFECTIVENESS

real-world-evidence-study
real-world-evidence-study

  • Approx. 33,000 patients with type 2 diabetes

  • 75% without CV disease

  • EMPRISE is a five year study program on the effectiveness, safety and healthcare utilization of empagliflozin in routine care across a spectrum of cardiovascular baseline risk using real-world data from three U.S. claims datasets

  1. Patorno E, Najafzadeh M, Pawar A, et al. The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care. Endocrinol Diabetes Metab. 2019;3(1):e00103. 

  2. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. (EMPA-REG OUTCOME® results and the publication’s Supplementary Appendix.)

  • *In addition to reducing the risk of CV death when added to the standard of care, JARDIANCE® also lowered glucose levels. In addition, JARDIANCE® demonstrated reduction in weight and blood pressure. JARDIANCE® is not indicated for weight loss or reduction in blood pressure.2
  • CI, confidence interval; CV, cardiovascular; GLP-1 RA; glucagon-like peptide-1 receptor agonists; HHF, heart failure hospitalization; HR, hazard ratio; RRR, relative risk reduction; US, United States

PC-IN-103695